Home > Name List By 4 > 4-[2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione

CAS No 21416-67-1 , 4-[2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione

  • Name: 4-[2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione
  • Synonyms: NSC129943;Razoxin; ICRF 159; 21416-67-1; 4,4'-Propylenebis(piperazine-2,6-dione); Razoxana; ICRF-159;4-[2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione; Cardioxan; Razoxanum;
  • CAS Registry Number:
  • Melting Point: 193 deg C
  • Flash Point: 275.3°C
  • Boiling Point: 531.5°Cat760mmHg
  • Density: 1.333g/cm3
  • Refractive index: 1.534
  • Safety Statements: Suspected human carcinogen producing leukemia and skin tumors. Moderately toxic by intraperitoneal route. Human effects: normocytic anemia and thrombocytopenia. Human mutation data reported. When heated to decomposition it emits toxic fumes of NOx.
  • Flash Point: 275.3°C
  • EINECS: 244-379-2
  • Molecular Weight: 268.26914
  • InchiKey: BMKDZUISNHGIBY-UHFFFAOYSA-N
  • InChI: InChI=1S/C11H16N4O4/c1-7(15-5-10(18)13-11(19)6-15)2-14-3-8(16)12-9(17)4-
    14/h7H,2-6H2,1H3,(H,12,16,17)(H,13,18,19)
  • Molecular Formula: C11H16N4O4
  • Molecular Structure:CAS No:21416-67-1 4-[2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione

Related products

Select to

21416-67-1 2,6-Piperazinedione,4,4'-(1-methyl-1,2-ethanediyl)bis-

  • China Shanghai Jinglan Chemical Co., Ltd. [Manufacturer]
  • Tel: 86-21-37789410
  • Fax: 86-21-64966973
  • Address: Room 513, 5th Floor, Building B,
    No. 18, Lane 1305, Huajing Road,
    Shanghai, 200231, P.R. China null,nullChina
Contact Supplier

21416-67-1 4,4'-Propylenebis(piperazine-2,6-Dione)

  • China Taizhou Crene Chempharm Co., Ltd. null
  • Tel: +86-(576)-88813233
  • Fax: +86-(576)-88670057
  • Address: Weiwu Load Economic Developed Zone, Taizhou, Zhejiang 318000, null,nullChina
Contact Supplier

21416-67-1 2,6-Piperazinedione,4,4'-(1-methyl-1,2-ethanediyl)bis-

Contact Supplier

Select to

1/1
References of 4-[2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione
Title: Razoxane
CAS Registry Number: 21416-67-1
CAS Name: 4,4￠-(1-Methyl-1,2-ethanediyl)bis-2,6-piperazinedione
Synonyms: (±)-4,4￠-propylenedi-2,6-piperazinedione; (±)-(3,5,3￠,5￠-tetraoxo)-1,2-dipiperazinopropane; (±)-1,2-bis(3,5-dioxopiperazinyl)propane
Manufacturers' Codes: ICI-59118; ICRF-159; NSC-129943
Molecular Formula: C11H16N4O4
Molecular Weight: 268.27
Percent Composition: C 49.25%, H 6.01%, N 20.88%, O 23.86%
Literature References: Cyclized analog of EDTA, q.v.; exhibits intracellular iron chelating activity. Plays role in preventing the formation of doxorubicin-iron complexes which generate radical oxygen species that are associated with cardiotoxicity. Prepn: A. M. Creighton et al., Nature 222, 384 (1969); idem, GB 1234935; idem, US 3941790 (1971, 1976 both to Natl. Res. Dev. Corp.). Mode of action: H. B. A. Sharpe et al., Nature 226, 524 (1970). Metabolism: R. E. Bellet et al., Eur. J. Cancer 13, 1293 (1977). Pharmacology: A. Atherton, ibid. 11, 383 (1975). Clinical studies: M. T. Bakowski et al., Int. J. Radiat. Oncol. Biol. Phys. 4, 115 (1978); H. W. Bruckner et al., Cancer Treat. Rep. 66, 1713 (1982). Toxicity study: E. Hassenstein, K. Renner, Strahlentherapie 154, 122 (1978). Clinical evaluation in renal cell cancer: J. P. Braybrooke et al., Clin. Cancer Res. 6, 4697 (2000). Review of antineoplastic activity and radiosensitization: M. T. Bakowski, Cancer Treat. Rev. 3, 95-107 (1976); K. Hellmann, W. Rhomberg, ibid. 18, 225-240 (1991).
Properties: Pale cream microcrystalline solid, mp 237-239°.
Melting point: mp 237-239°
 
Derivative Type: (+)-Form
CAS Registry Number: 24584-09-6
Synonyms: Dexrazoxane
Manufacturers' Codes: ADR-529; ICRF-187; NSC-169780
Trademarks: Zinecard (Pfizer)
Literature References: Clinical pharmacokinetics: R. H. Earhart et al., Cancer Res. 42, 5255 (1982). HPLC determn in plasma and urine: R. C. Lewis et al., Pharm. Res. 9, 101 (1992). Clinical study of protection vs doxorubicin-associated cardiomyopathy: J. L. Speyer et al., J. Clin. Oncol. 10, 117 (1992); S. E. Lipshultz et al., N. Engl. J. Med. 351, 145 (2004). Review of pharmacology and clinical studies: J. Koning et al., Cancer Treat. Rev. 18, 1-19 (1991); of therapeutic role as a cardioprotectant: S. M. Swain, P. Vici, J. Cancer Res. Clin. Oncol. 130, 1-7 (2004).
Properties: Crystals from aq methanol/ether, mp 193°. [a]D +11.35° (c = 5 in DMF). Soly (mg/ml): 10-12 water, 35-43 0.1N HCl, 25-34 0.1N NaOH, 6.7-10 10% ethanol, 1 methanol, 7.1-10 H2O/DMA (1:1), 9.7-14.5 0.1M citrate buffer (pH 4), 8.7-13 0.1M borate buffer (pH 9). pKa 2.1. Partition coefficient (octanol/water): 0.025. Degrades rapidly above pH 7.0.
Melting point: mp 193°
pKa: pKa 2.1
Optical Rotation: [a]D +11.35° (c = 5 in DMF)
Log P: Partition coefficient (octanol/water): 0.025
 
Derivative Type: (+)-Form hydrochloride
CAS Registry Number: 149003-01-0
Trademarks: Cardioxane (Chiron); Eucardion (Domp?
 
Therap-Cat: Racemate as antineoplastic. (+)-Form as cardioprotectant.
Keywords: Antineoplastic; Topoisomerase II Inhibitor.